| Ytd | -2.66% | |
| 1y | 147.04% |
| Open | 150.94 | Prev Close | 151.72 | Low | 150.94 | High | 158.39 | Mkt Cap | 6.27B |
| Vol | 146.17K | Avg Vol | 197.66K | EPS | -2.74 | P/E | N/A | Forward P/E | 72.71 |
| Beta | -1.23 | Short Ratio | 6.37 | Inst. Own | 24.17% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 156.24 | 200-d Avg | 156.51 | 1yr Est | 214.00 |
BLTE News
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “C
SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “C
Morgan Stanley analyst Judah Frommer maintains Belite Bio (NASDAQ:BLTE) with a Overweight and rai
Cantor Fitzgerald analyst Steve Seedhouse maintains Belite Bio (NASDAQ:BLTE) with a Overweight an
Belite Bio, Inc (BLTE) Q2 2026 Earnings Call Transcript
Belite Bio NASDAQ: BLTE said the U.S. Food and Drug Administration has accepted its New Drug Applica
Belite Bio (NASDAQ:BLTE) reported second-quarter financial results on Thursday. The transcript from
Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.54) per share which beat the analyst conse
SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “C
Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in
Wall Street analysts change outlook on top names. HC Wainwright raises price target for Belite Bio,
HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises
SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “C
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “C
Belite Bio (BLTE) is positioned for upside with tinlarebant, an oral therapy for Stargardt disease,
Panelists at the H.C. Wainwright Sixth Annual Ophthalmology Virtual Conference said investigational
Belite Bio (BLTE) stock jumps 3% on positive Phase 3 DRAGON trial data for its Stargardt disease dru
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “C
Belite Bio NASDAQ: BLTE Chief Medical Officer Hendrik Scholl said the company is advancing its lead
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “C
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “C
HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and mainta
SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) ("Belite Bio" or the "Co
Belite Bio, Inc (BLTE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Trans
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “C
Mizuho analyst Graig Suvannavejh maintains Belite Bio (NASDAQ:BLTE) with a Outperform and lowers
HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and mainta
Belite Bio, Inc (BLTE) Q1 2026 Earnings Call Transcript
Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.45) per share which beat the analyst conse
Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio®" or the "Company"), a clinical-stage dru
Belite Bio, Inc. (NASDAQ:BLTE), ("Belite Bio®" or the "Company"), a clinical-stage b
HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and mainta
Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug
HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and mainta
HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises
Morgan Stanley analyst Judah Frommer maintains Belite Bio (NASDAQ:BLTE) with a Overweight and rai
Cantor Fitzgerald analyst Steve Seedhouse maintains Belite Bio (NASDAQ:BLTE) with a Overweight an
Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.70) per share which missed the analyst con
HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and mainta
B of A Securities analyst Tazeen Ahmad initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy
Morgan Stanley analyst Judah Frommer initiates coverage on Belite Bio (NASDAQ:BLTE) with a Overwe
Mizuho analyst Graig Suvannavejh upgrades Belite Bio (NASDAQ:BLTE) from Neutral to Outperform and
Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug